Our Medicines

Harnessing the Power of Native Phages

PhagenCorp has developed patent-pending therapeutics, thought to activate epigenetic changes in naturally occurring, “native” phages, that already reside within the patient. These epigenetic changes appear to cause the native phages to revert from lysogenic activities to lytic swarming to rapidly eliminate the targeted microbes within the patient

Inducing the “Impossible” Towards Greater Possibilities.

In addition to our INPT medicines, we’ve also researching Induced Native Virolytic Therapy, a technique that encourages bacteria in the microbiome to produce virolytic chemicals powerful enough to kill harmful viruses. Unlike INPT, INVT does not use phages of any kind, instead inducing and stimulating bacteria to eradicate specific, targeted viruses.

Each medication listed here is microbe specific, allowing it the best possible opportunity to work effectively.

100+ Medicines & Counting (research products only)

  • Mixed Bartonella
  • Bartonella bacilliformis
  • Bartonella henselae
  • Borrelia afzelii
  • Borrelia bavariensis
  • Borrelia bissettii
  • Borrelia burgdorferi
  • Borrelia carteri
  • Borrelia caucasica
  • Borrelia crocidurae
  • Borrelia duncani
  • Borrelia garinii
  • Borrelia hermanii
  • Borrelia hermsii
  • Borrelia kansasii
  • Borrelia miyamotoi
  • Borrelia parkeri
  • Borrelia persica
  • Borrelia recurrentis
  • Borrelia-Relapsing Fever (Group)
  • Borrelia valaisiana
  • Mixed Borrelia
  • Campylobacter Jejuni
  • Clostridium difficile
  • Clostridium Diptheriae
  • Clostridium tetani
  • Enterococcus faecalis
  • Ehrlichia HME/HE
  • Escherichia coli
  • H. Pylori
  • Haemophilus influenzae
  • Legionella pneumophila
  • Morgan Gaertner
  • Morgan Pure
  • MRSA
  • Mycobacterium avium
  • Mycobacterium chimaera
  • Mycobacterium tuberculosis
  • Mycobacterium Kansasii
  • Mycoplasma fermentans Incog.
  • Mycoplasma pneumoniae
  • Pseudomonas Aeruginosa
  • Pseudotuberculosis
  • Rickettsia Rickettsii
  • Salmonella Typhi
  • Staph Aureus
  • Staph Albus
  • Staph haemolyticus
  • Strep B
  • Strep Faecal
  • Strep pneumoniae
  • Strep Salivarius
  • Aspergillus Clavatus
  • Aspergillus Favus
  • Candida albicans
  • Candida Tropicalis
  • Candida parapsilosis
  • Candida pseudotropicalis
  • Cladosporium
  • Penicillium
  • Rhizopus
  • Rhodotorula
  • Rhizopus
  • Smuts
  • Wallemia Mix
  • Ancylostoma caninum
  • Ascaris lumbricoides
  • Babesia microti
  • Echinostoma trivolvis
  • Fasciola hepatica
  • Plasmodium falciparum
  • Plasmodium malariae
  • Plasmodium vivax
  • Strongyloides
  • Taenia solium
  • Toxoplasma Gondii

News & Research Updates

Exclusive access to the latest information regarding PhagenCorp’s research trials, commercial opportunities, and biotechnology innovations.
Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.

By submitting my data I agree to be contacted

Keep up with us!

Sign up for our mailing list or follow us on social media to keep up with all of the latest happenings here at PhagenCorp!

We are committed to earning and maintaining our place at the forefront of medical innovation and excellence by providing constant, continued, and groundbreaking solutions for the abolition of disease.


Phage-Biotechnology & Precision Medicine Innovation